Sanofi Fires Up Late-Stage R&D After Growth Rekindled in Fourth Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Nine late-stage products are expected to lead Sanofi’s future evolution into a developer primarily of biologics, including alirocumab for hypercholesterolemia, dupilumab for atopic dermatitis and asthma, and sarilumab for rheumatoid arthritis.
You may also be interested in...
Genzyme Will Appeal Lemtrada “Complete Response” After FDA Seeks More Trials
Rater-blinded design for multiple sclerosis claim netted an approval in Europe but a rejection by FDA, which was concerned about bias related to open label studies.
Aelix Therapeutics' Multi-Vector Therapeutic HIV Vaccine Could Be Backbone Of Combination Strategy
Emerging Company Profile: Aelix Therapeutics has constructed a potential therapeutic HIV vaccine to refocus the immune system onto vulnerable parts of the virus, and may allow patients to control viral replication without antiretroviral therapy.
Pipeline Watch: Phase III Readouts For COVID-19, Dry Eye Disease, Uveal Melanoma
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.